Skip to main content
Premium Trial:

Request an Annual Quote

AMDL Inks Sub-licensing Deal for HPV Kit in Asian Markets

NEW YORK (GenomeWeb News) – The molecular diagnostics company AMDL said today that it has licensed a human papillomavirus diagnostic genotyping test from MyGene International for use in Asia.
Under the exclusive sublicense agreement, AMDL will use MyGene’s HPV Chip Kit patents to make, market, sell, and distribute the MyGene HPV Test Kit in China, Taiwan, Singapore, Malaysia, Thailand, Cambodia, and Vietnam.
AMDL is based in Tustin, Calif., but also has operations in three cities in China. The company’s Chinese branch is run through its subsidiary, Jade Pharmaceutical International.
AMDL said an “extremely conservative” estimate for a market for HPV testing in China could be around $50 million. The company also said that there are around 330 million women infected with HPV in the world, and that 70 percent of the existing infections are in Asian populations.
Financial terms of the agreement were not released.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.